PFIZER INC (PFE)
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - General
Pfizer Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 29.07 | 29.43 | 28.54 | 29.39 | 48,319,586 |
| Nov 5, 2026 | 31.09 | 31.44 | 29.85 | 29.88 | 53,051,021 |
| Nov 4, 2026 | 30.75 | 30.90 | 30.04 | 30.79 | 49,921,028 |
| Nov 3, 2026 | 30.68 | 31.06 | 29.89 | 30.00 | 53,059,340 |
| Nov 2, 2026 | 30.45 | 31.04 | 30.20 | 30.67 | 50,818,540 |
| Oct 30, 2026 | 30.51 | 30.67 | 30.14 | 30.52 | 45,485,398 |
| Oct 29, 2026 | 29.99 | 30.18 | 29.61 | 29.95 | 34,259,422 |
| Oct 28, 2026 | 29.49 | 29.82 | 29.22 | 29.45 | 27,260,376 |
| Oct 27, 2026 | 29.54 | 29.86 | 29.51 | 29.80 | 25,592,918 |
| Oct 26, 2026 | 30.00 | 30.30 | 29.71 | 29.79 | 25,656,349 |
| Oct 23, 2026 | 30.28 | 30.32 | 29.81 | 30.03 | 29,484,130 |
| Oct 22, 2026 | 30.05 | 30.44 | 29.88 | 30.42 | 28,703,382 |
| Oct 21, 2026 | 30.00 | 30.09 | 29.69 | 29.85 | 22,217,676 |
| Oct 20, 2026 | 29.67 | 30.25 | 29.59 | 30.11 | 34,442,162 |
| Oct 19, 2026 | 29.30 | 29.69 | 29.25 | 29.44 | 20,816,618 |
| Oct 16, 2026 | 29.72 | 29.74 | 29.42 | 29.58 | 28,627,477 |
| Oct 15, 2026 | 29.57 | 29.88 | 29.42 | 29.44 | 32,890,960 |
| Oct 14, 2026 | 28.60 | 29.49 | 28.55 | 29.21 | 39,370,506 |
| Oct 13, 2026 | 28.61 | 28.61 | 28.13 | 28.37 | 26,837,187 |
| Oct 12, 2026 | 28.42 | 28.50 | 28.28 | 28.40 | 18,555,612 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Chairman & CEO | Grant/Award | 20 | $610.4 | Oct 30, 2026 | |
| Chairman & CEO | Grant/Award | 20 | $588.8 | Oct 15, 2026 | |
| Chairman & CEO | Grant/Award | 71 | $2.0K | Oct 13, 2026 | |
| Chairman & CEO | Grant/Award | 21 | $598.92 | Sep 30, 2026 | |
| Director | Grant/Award | 1.4K | $38.7K | Sep 25, 2026 | |
| Director | Grant/Award | 1.6K | $45.0K | Sep 25, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 529.7M | 9.3% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jan 2024 | 434.7M | 7.6% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 372.1M | 6.5% | 13F |
STATE STREET CORP | 307.1M | 5.4% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 137.5M | 2.4% | 13F |
VANGUARD PORTFOLIO MANAGEMENT LLC | 119.2M | 2.1% | 13F |
Fisher Asset Management, LLC | 112.1M | 2.0% | 13F |
MORGAN STANLEY | 96.3M | 1.7% | 13F |
NORGES BANK | 61.5M | 1.1% | 13F |
NORTHERN TRUST CORP | 59.1M | 1.0% | 13F |
Insiders
- BOURLA ALBERTChairman & CEO
- Quincey JamesDirector
- SMITH JAMES CDirector
- Taraporevala CyrusDirector
- Echevarria JosephDirector
- NARAYEN SHANTANUDirector
- Buckley Mortimer JDirector
- BLAYLOCK RONALD EDirector
- DAMICO JENNIFER B.SVP & Controller
- Desmond-Hellmann SusanDirector
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide.
Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis.
The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family.
The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division.
Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations.
The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
based on 5.70B shares outstanding
30d Avg
34.77M
60d Avg
33.68M
90d Avg
33.68M